CTSU CALGB 80405-A Phase III Trial of Irinotecan/5-FU Leucovorin or Oxaliplatin + 5-FU/Leucovorin with Bevacizumab, or Cetuximab or with The Combination for Patients with Untreated Metastatic Adenocarcinoma of The Colon or Rectum.
CTSU CALGB 80405
Physician choice of FOLFOX or FOLFIRI with Bevacizumab, randomized to get with/without Cetuximab.
Must send tissue for KRAS testing.
Please contact Tricia Montgomery, RN for additional inclusion/exclusion criteria.